IL151932A0 - Use of fulvestrant in the treatment of resistant breast cancer - Google Patents
Use of fulvestrant in the treatment of resistant breast cancerInfo
- Publication number
- IL151932A0 IL151932A0 IL15193201A IL15193201A IL151932A0 IL 151932 A0 IL151932 A0 IL 151932A0 IL 15193201 A IL15193201 A IL 15193201A IL 15193201 A IL15193201 A IL 15193201A IL 151932 A0 IL151932 A0 IL 151932A0
- Authority
- IL
- Israel
- Prior art keywords
- fulvestrant
- treatment
- breast cancer
- resistant breast
- resistant
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title abstract 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008172.9A GB0008172D0 (en) | 2000-04-05 | 2000-04-05 | Therapy |
| PCT/GB2001/001500 WO2001074366A1 (en) | 2000-04-05 | 2001-04-02 | Use of fulvestrant in the treatment of resistant breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL151932A0 true IL151932A0 (en) | 2003-04-10 |
Family
ID=9889101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15193201A IL151932A0 (en) | 2000-04-05 | 2001-04-02 | Use of fulvestrant in the treatment of resistant breast cancer |
| IL151932A IL151932A (en) | 2000-04-05 | 2002-09-25 | Use of folvestrant for the preparation of a drug for the treatment of resistant breast cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL151932A IL151932A (en) | 2000-04-05 | 2002-09-25 | Use of folvestrant for the preparation of a drug for the treatment of resistant breast cancer |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20030158166A1 (zh) |
| EP (2) | EP1272195B1 (zh) |
| JP (1) | JP2003528919A (zh) |
| KR (1) | KR100757764B1 (zh) |
| CN (1) | CN1431905A (zh) |
| AT (1) | ATE306270T1 (zh) |
| AU (2) | AU2001244372B2 (zh) |
| BR (1) | BR0109789A (zh) |
| CA (1) | CA2403608A1 (zh) |
| CH (1) | CH1272195H1 (zh) |
| CZ (1) | CZ303096B6 (zh) |
| DE (1) | DE60113975T2 (zh) |
| DK (1) | DK1272195T3 (zh) |
| EE (1) | EE05026B1 (zh) |
| ES (1) | ES2248300T3 (zh) |
| GB (1) | GB0008172D0 (zh) |
| HK (1) | HK1051498A1 (zh) |
| HU (1) | HU230064B1 (zh) |
| IL (2) | IL151932A0 (zh) |
| IS (1) | IS2869B (zh) |
| MX (1) | MXPA02009744A (zh) |
| NO (1) | NO329949B1 (zh) |
| NZ (1) | NZ539603A (zh) |
| PL (1) | PL201175B1 (zh) |
| RU (1) | RU2265438C2 (zh) |
| SK (1) | SK287779B6 (zh) |
| UA (1) | UA80388C2 (zh) |
| WO (1) | WO2001074366A1 (zh) |
| ZA (1) | ZA200207538B (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| CA2453111A1 (en) * | 2001-07-07 | 2003-01-23 | Alan Marshall Irving | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
| US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
| US8324194B2 (en) * | 2005-11-22 | 2012-12-04 | Incyte Corporation | Combination therapy for the treatment of cancer |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| MX2013013104A (es) * | 2011-05-09 | 2014-10-15 | Univ Virginia Patent Found | Composiciones y metodos para el tratamiento de cancer. |
| MX2013013558A (es) | 2011-05-20 | 2013-12-16 | Capital Business Y Gestion De Finanzas S L | Composicion farmaceutica. |
| WO2015106094A1 (en) * | 2014-01-10 | 2015-07-16 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| TWI793165B (zh) | 2017-09-11 | 2023-02-21 | 美商阿托薩醫療公司 | 製造及使用因多昔芬(endoxifen)之方法 |
| AU2019274815A1 (en) * | 2018-05-24 | 2021-01-21 | Shivanka Research LLC | Prodrugs of fulvestrant |
| US20230255974A1 (en) * | 2020-02-29 | 2023-08-17 | The University Of Vermont | Use of thyromimetics for the treatment of cancer |
-
2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
-
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en active IP Right Grant
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko active IP Right Grant
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
-
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
-
2003
- 2003-05-27 HK HK03103770A patent/HK1051498A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1500001I1 (hu) | ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére | |
| ATE430570T1 (de) | Synergistische kombinationstherapie zur krebsbehandlung | |
| EP1355563A4 (en) | METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES | |
| EP1427377A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISEASES USING BINDERS SPECIFIC TO THE PROSTATE-SPECIFIC MEMBRANEANT | |
| IL164599A0 (en) | Combination therapy for the treatment of cancer | |
| KR970704430A (ko) | 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity) | |
| EP1077704A4 (en) | COMBINATION THERAPY FOR TREATING DEPRESSION | |
| HK1051498A1 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
| IL159887A0 (en) | Combination therapy for the treatment of cancer | |
| MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
| IL158206A0 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
| HK1043058A1 (zh) | 異環磷酰胺芥子類似物及其用途 | |
| PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
| HUP0301123A3 (en) | Use of exemestane for treatment of hormone-dependent breast cancer | |
| EP1409734A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER | |
| EP1684795A4 (en) | METHODS AND AGENTS FOR THE TREATMENT OF CANCER | |
| IL151493A0 (en) | Use of dermaciclane for the treatment of anxiety and depression | |
| PL354111A1 (en) | Combined therapy for treating the both depression and anxiety | |
| SI1272195T1 (sl) | Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk | |
| GB9826603D0 (en) | Device for treatment, especially putting in plaster, of patients limb | |
| GB0115943D0 (en) | Treatment and diagosis of cancer | |
| AU2002313029A1 (en) | Apparatus for skin stimulation and treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |